Robert E Steinert1, Maria F Landrock2, Sina S Ullrich3, Scott Standfield3, Bärbel Otto4, Michael Horowitz3, Christine Feinle-Bisset3. 1. University of Adelaide Discipline of Medicine, Adelaide, Australia; National Health and Medical Research Council of Australia, Centre of Research Excellence in Translating Nutritional Science to Good Health, Adelaide, Australia; and re.steinert@gmail.com. 2. University of Adelaide Discipline of Medicine, Adelaide, Australia; 3. University of Adelaide Discipline of Medicine, Adelaide, Australia; National Health and Medical Research Council of Australia, Centre of Research Excellence in Translating Nutritional Science to Good Health, Adelaide, Australia; and. 4. Medizinische Klinik und Poliklinik IV, Klinikum der Universität München-Campus Innenstadt, Munich, Germany.
Abstract
BACKGROUND:Branched-chain amino acids (BCAAs), particularly leucine, act as nutrient signals regulating protein synthesis and degradation as well as glucose metabolism. In addition, leucine has been demonstrated in animal experiments to modulate eating and energy homeostasis. OBJECTIVE: We aimed to characterize the effects of physiologic and supraphysiologic loads of intraduodenal leucine on eating, gut hormone and motor functions, and blood glucose in humans. DESIGN:Twelve lean men were studied on 3 occasions in a randomized, double-blind order. Antropyloroduodenal motility, plasma ghrelin, cholecystokinin, glucagon-like peptide 1, peptide YY, insulin, glucagon, blood glucose, appetite perceptions, and gastrointestinal symptoms were measured during 90-min intraduodenal infusions of leucine at 0.15 kcal/min (total 3.3 g, 13.5 kcal), 0.45 kcal/min (total 9.9 g, 40.5 kcal), or saline (control). Ad libitum eating from a buffet lunch was quantified immediately after the infusions. RESULTS:Leucine at 0.45 kcal/min inhibited eating (energy intake by ∼13%, P < 0.05), increased plasma cholecystokinin, slightly reduced blood glucose and increased plasma insulin, and decreased antral pressures (all P < 0.05). Leucine at 0.15 kcal/min had no effect on food intake, blood glucose, or antral pressures but also slightly increased plasma cholecystokinin (P < 0.05). Neither dose affected plasma ghrelin, glucagon, glucagon-like peptide 1 and peptide YY, or pyloric and duodenal pressures. Plasma leucine concentrations were related to the dose of intraduodenal leucine, with substantial increases during both 0.15 and 0.45 kcal/min. CONCLUSIONS: The effects of intraduodenal infusions of free leucine on eating are probably not primarily mediated by changes in gut motor and hormone functions, with perhaps the exception of cholecystokinin. Instead, increased plasma leucine concentrations may be a potential signal mediating the eating-inhibitory effect of leucine. The study was registered as a clinical trial with the Australia and New Zealand Clinical Trial Registry (www.anzctr.org.au) as ACTRN12613000899741.
RCT Entities:
BACKGROUND:Branched-chain amino acids (BCAAs), particularly leucine, act as nutrient signals regulating protein synthesis and degradation as well as glucose metabolism. In addition, leucine has been demonstrated in animal experiments to modulate eating and energy homeostasis. OBJECTIVE: We aimed to characterize the effects of physiologic and supraphysiologic loads of intraduodenal leucine on eating, gut hormone and motor functions, and blood glucose in humans. DESIGN: Twelve lean men were studied on 3 occasions in a randomized, double-blind order. Antropyloroduodenal motility, plasma ghrelin, cholecystokinin, glucagon-like peptide 1, peptide YY, insulin, glucagon, blood glucose, appetite perceptions, and gastrointestinal symptoms were measured during 90-min intraduodenal infusions of leucine at 0.15 kcal/min (total 3.3 g, 13.5 kcal), 0.45 kcal/min (total 9.9 g, 40.5 kcal), or saline (control). Ad libitum eating from a buffet lunch was quantified immediately after the infusions. RESULTS:Leucine at 0.45 kcal/min inhibited eating (energy intake by ∼13%, P < 0.05), increased plasma cholecystokinin, slightly reduced blood glucose and increased plasma insulin, and decreased antral pressures (all P < 0.05). Leucine at 0.15 kcal/min had no effect on food intake, blood glucose, or antral pressures but also slightly increased plasma cholecystokinin (P < 0.05). Neither dose affected plasma ghrelin, glucagon, glucagon-like peptide 1 and peptide YY, or pyloric and duodenal pressures. Plasma leucine concentrations were related to the dose of intraduodenal leucine, with substantial increases during both 0.15 and 0.45 kcal/min. CONCLUSIONS: The effects of intraduodenal infusions of free leucine on eating are probably not primarily mediated by changes in gut motor and hormone functions, with perhaps the exception of cholecystokinin. Instead, increased plasma leucine concentrations may be a potential signal mediating the eating-inhibitory effect of leucine. The study was registered as a clinical trial with the Australia and New Zealand Clinical Trial Registry (www.anzctr.org.au) as ACTRN12613000899741.
Authors: L G Trahair; C S Marathe; S Standfield; C K Rayner; C Feinle-Bisset; M Horowitz; K L Jones Journal: Int J Obes (Lond) Date: 2016-12-06 Impact factor: 5.095
Authors: Davide Zanchi; Anne Christin Meyer-Gerspach; Claudia Suenderhauf; Katharina Janach; Carel W le Roux; Sven Haller; Jürgen Drewe; Christoph Beglinger; Bettina K Wölnerhanssen; Stefan Borgwardt Journal: Sci Rep Date: 2016-10-20 Impact factor: 4.379
Authors: Rachel A Elovaris; Vida Bitarafan; Shahram Agah; Sina S Ullrich; Kylie Lange; Michael Horowitz; Christine Feinle-Bisset Journal: Nutrients Date: 2021-05-11 Impact factor: 5.717
Authors: Jennifer Wilbrink; Gwen Masclee; Tim Klaassen; Mark van Avesaat; Daniel Keszthelyi; Adrian Masclee Journal: Nutrients Date: 2021-05-11 Impact factor: 5.717
Authors: Gudrun Schober; Kylie Lange; Robert E Steinert; Amy T Hutchison; Natalie D Luscombe-Marsh; Maria F Landrock; Michael Horowitz; Radhika V Seimon; Christine Feinle-Bisset Journal: Physiol Rep Date: 2016-09